SCHEMBL24879349

SCHEMBL24879349

CCOC(=O)CCSc1ccc2nc[nH]c(=O)c2c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.40
▸ HPGD P15428 6/20 0.40
▸ MAPT P10636 3/20 0.40
▸ GLA P06280 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ GAA P10253 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 3/20 0.38
▸ PARP1 P09874 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HSD17B10 Q99714 4/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ TNF P01375 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27458190 0.89 PARP1 (0.39) KDM4EHPGDMAPTPOLBKMT2A
SCHEMBL24878867 0.84 CYP3A4 (0.42) ALDH1A1LMNAPARP1HSD17B10TDP1
SCHEMBL30987312 0.84 CYP3A4 (0.42) ALDH1A1LMNAPARP1HSD17B10TDP1
SCHEMBL24879352 0.83 HPGD (0.43) KDM4EHPGDMAPTGLAPOLB
SCHEMBL24879116 0.75 TNF (0.54) KDM4EHPGDMAPTGLAPOLB
SCHEMBL27132794 0.73 KMT2A (0.45) KDM4EHPGDMAPTGLAPOLB
SCHEMBL23663597 0.72 HPGD (0.39) KDM4EHPGDMAPTGLAPOLB
SCHEMBL23663686 0.71 MAPT (0.44) KDM4EHPGDMAPTGLAPOLB
SCHEMBL21919495 0.71 KDM4E (0.42) KDM4EHPGDMAPTGLAPOLB
SCHEMBL22303058 0.70 ALDH1A1 (0.42) KDM4EHPGDMAPTGLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
CN-117916242-A SHP2 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-04-19 — — CN disclosed
WO-2023282702-A1 SHP2 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 KDM4E 1134/4885HPGD 3623/4885MAPT 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback